Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-007875

Chief Financial Officer sold 29,700 shares at an average $60.16 ($1,786,636)

  • Chief Financial Officer acquired 29,700 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Prasad Raju · Chief Financial Officer

Table I: Non-derivative

5 lines
Date Transaction Shares Price Value Owned after D/I
2026-01-06 Exercise or conversion : show line 1 in the form 10b5-1 +23,361 $45.15 $1,054,749 30,128 D
2026-01-06 Exercise or conversion : show line 2 in the form 10b5-1 +6,339 $44.31 $280,881 36,467 D
2026-01-06 Sale : show line 3 in the form 10b5-1 −18,933 $60.18 $1,139,386 17,534 D
2026-01-06 Sale : show line 4 in the form 10b5-1 −5,004 $60.00 $300,240 12,530 D
2026-01-06 Sale : show line 5 in the form 10b5-1 −5,763 $60.21 $347,010 6,767 D
Open-market sales · 29,700 sh · avg $60.16 · $1,786,636

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2026-01-06 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) −23,361 76,639 D
2026-01-06 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −6,339 7,493 D
Loading xslF345X05/ownership.xml…